Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 5

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 3Sarcoma 2Gastrointestinal 2

Conditions

Carcinoma, Renal Cell 3Neoplasm Metastasis 2Gastrointestinal Stromal Tumors 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Gastrointestinal Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 66Carboplatin 65Paclitaxel 54Magnetic Resonance Spectroscopy 45Cisplatin 45Specimen Handling 43Gemcitabine 36Docetaxel 31Bevacizumab 31Leucovorin 29Doxorubicin 29Dexamethasone 28Fluorouracil 27Pemetrexed 26Cyclophosphamide 26Oxaliplatin 24Radiation 23durvalumab 22Radiotherapy 22Letrozole 22Etoposide 22Nivolumab 21Irinotecan 21Vincristine 20Rituximab 20Capecitabine 20Taxes 19Prednisone 19Lenalidomide 19130-nm albumin-bound paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Sunitinib × 30 days × Clear all
NCT02231749 2026-05-27

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Bristol-Myers Squibb

Phase 3 Completed
1,096 enrolled 17 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT07218926 2026-05-27

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GlaxoSmithKline

Phase 3 Recruiting
450 enrolled
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT03260894 2026-05-22

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Incyte Corporation

Phase 3 Completed
129 enrolled 13 charts
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05043090 2026-05-22

SAMETA

AstraZeneca

Phase 3 Active not recruiting
148 enrolled
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT05208047 2026-05-22

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Cogent Biosciences, Inc.

Phase 3 Active not recruiting
482 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡